RxDoctor Payments Data

Ryan Brandt, MD

Cardiovascular Disease · Santa Cruz, CANPI 1518946664

Payments from drug & device makers

$22,011in general payments, 2019–2025

Across 284 payments — averaging $77.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Shockwave Medical, Inc$7K
  • Philips North America LLC$1K
  • Biotronik Inc.$1K
  • Abbott$762
  • Penumbra, Inc.$717
  • plus $1K from 9 others

What the payments were for

  • Speaking & faculty fees$6,60030%
  • Travel & lodging$7,04832%
  • Food & beverage$8,36438%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,011 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$897,864
Medicare patients
3,016
Services billed
16,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,263$1,504,590
EntrestoSacubitril/Valsartan461$556,902
XareltoRivaroxaban186$200,238
JardianceEmpagliflozin158$171,348
Repatha SureclickEvolocumab76$74,104
Praluent PenAlirocumab54$50,962
Metoprolol Succinate1,125$21,842
FarxigaDapagliflozin Propanediol26$17,302
NexletolBempedoic Acid23$12,067
Diltiazem 24hr Er (Cd)Diltiazem Hcl255$11,537
Dabigatran EtexilateDabigatran Etexilate Mesylate41$10,859
Atorvastatin Calcium748$9,137
Rosuvastatin Calcium449$9,101
Ezetimibe199$7,094
PradaxaDabigatran Etexilate Mesylate15$6,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$24$200,238186 claims
Boehringer IngelheimJardiance, Pradaxa$90$177,403173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Cruz

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →